All Wales Medicines Strategy Group

Grŵp Strategaeth Meddyginiaethau Cymru Gyfan

Final Appraisal Recommendation

Advice No: 2914 – October 2014

Alogliptin (Vipidia®▼) 6.25 mg, 12.5 mg and 25 mg film-coated tablets

Submission by Takeda UK Ltd

Recommendation of AWMSG

Alogliptin (Vipidia®▼) is recommended as an option for restricted use for dual oral therapy within NHS Wales.

Alogliptin (Vipidia®▼) should be restricted for use in the following circumstances within its licensed indication for the treatment of adults aged 18 years and older with type 2 diabetes mellitus to improve glycaemic control in combination with other glucose lowering medicinal products including insulin, when these, together with diet and exercise, do not provide adequate glycaemic control:

- **In combination with metformin (dual therapy), when metformin alone, together with diet and exercise does not provide adequate glycaemic control in patients for whom the addition of a sulphonylurea is inappropriate;**
- **In combination with a sulphonylurea (dual therapy), when a sulphonylurea alone, together with diet and exercise does not provide adequate glycaemic control in patients for whom the addition of metformin is inappropriate.**

Alogliptin (Vipidia®▼) is not recommended for use within NHS Wales outside of these circumstances.

In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 857), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.

This recommendation has been ratified by Welsh Government and will be considered for review every three years.

Marketing authorisation holder on first issue	Takeda UK Ltd
Date of first issue	October 2014
Last reviewed	December 2017